FİDAN, S. Et Al. 2021. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.24, no.2 , 254-259.

FİDAN, S., ÇAPKIN, E., Arica, D., DURAK, S., & Okatan, I. E., (2021). Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.24, no.2, 254-259.

FİDAN, SAMİ Et Al. "Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy," INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.24, no.2, 254-259, 2021

FİDAN, SAMİ Et Al. "Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy." INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.24, no.2, pp.254-259, 2021

FİDAN, S. Et Al. (2021) . "Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy." INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.24, no.2, pp.254-259.

@article{article, author={SAMİ FİDAN Et Al. }, title={Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy}, journal={INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES}, year=2021, pages={254-259} }